Yes, you can wear contact lenses, but remove them before instilling the drop and wait at least 15 minutes before reinserting to avoid dilution of the medication.
Persistent redness may indicate irritation or an allergic response. Stop the medication and seek an ophthalmic review to determine the cause and appropriate management.
Bimatoprost is not routinely recommended for children under 12 years of age. Its safety and efficacy have not been established in younger pediatric populations.
Most patients experience a measurable IOP reduction within 8-12 hours after the first dose, with the full effect typically stabilizing after several weeks of consistent use.
Long-term use can lead to a gradual darkening of the iris, especially in patients with mixed-colour irides. This change is usually permanent.
The medication is supplied in a clear, plastic ophthalmic bottle containing 3 ml of sterile solution, equipped with a dropper tip for single-drop dosing.
No specific restrictions exist, but keep the bottle in its original packaging and ensure it remains sealed to prevent leakage during pressure changes.
Bimatoprost often provides a greater IOP-lowering effect than beta-blockers or carbonic anhydrase inhibitors, but individual response varies; a specialist can tailor therapy based on efficacy and tolerability.
Yes, multiple glaucoma medications can be combined, but they should be administered at least five minutes apart and under ophthalmic supervision to monitor additive effects.
An unopened bottle remains stable until the expiration date printed on the label, usually 24 months from the date of manufacture, provided it is stored in a cool, dry place.
Bimat + Applicators is a topical ophthalmic solution that contains bimatoprost as its active ingredient. Bimatoprost belongs to the prostaglandin-analogue class of eye-care medicines and is supplied in a 3 ml bottle with a drop-per-applicator. In the United Kingdom, it is classified as a prescription-only medication (POM) and is regulated by the Medicines and Healthcare products Regulatory Agency (MHRA).
Bimatoprost mimics the activity of naturally occurring prostaglandin F2α. When a drop is placed on the eye’s surface, the drug penetrates the cornea and reaches the trabecular meshwork, the primary drainage pathway for aqueous humour.
Onset of pressure reduction typically occurs within a few hours, with the maximal effect observed after 8-12 hours. The drug’s half-life in ocular tissues is short, but the structural changes it induces persist, allowing once-daily dosing.
These indications are endorsed by the MHRA and align with the approved uses of bimatoprost in the UK. The medication is intended for adult patients for whom a single-drop, once-daily regimen is appropriate.
Bimatoprost is also approved in some markets (e.g., the United States) for enhancing eyelash growth under the brand name Latisse. In the UK, using bimatoprost eye drops for cosmetic eyelash lengthening is considered off-label.
This article provides educational information about Bimat + Applicators and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
